Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs
| Autor: | Adam J. Folbe, Peter F. Svider, Andrew M. Fribley, Michael A. Blasco, Pankhoori Saraf, John R. Jacobs, Soly Baredes, S. Naweed Raza, Jean Anderson Eloy |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Cetuximab business.industry Head and neck cancer Phases of clinical research Pembrolizumab medicine.disease Systemic therapy Head and neck squamous-cell carcinoma Clinical trial stomatognathic diseases 03 medical and health sciences 0302 clinical medicine Otorhinolaryngology 030220 oncology & carcinogenesis Internal medicine medicine 030212 general & internal medicine Nivolumab business medicine.drug |
| Zdroj: | The Laryngoscope. 127:2565-2569 |
| ISSN: | 0023-852X |
| DOI: | 10.1002/lary.26629 |
| Popis: | Objectives Despite dramatic developments in drugs established for other malignancies, historically there have been few novel systemic agents available for the management of head and neck squamous cell carcinoma (HNSCC). However, the last decade has observed increased interest in targeted therapies for HNSCC. In 2006, cetuximab became the first major drug for HNSCC to gain Food and Drug Administration (FDA) approval in 3 decades. Recently, both pembrolizumab and nivolumab gained FDA approval for treatment of recurrent or metastatic HNSCC, and trials for other indications in HNSCC are actively underway. As older agents including cisplatin and 5-fluorouracil continue to play a significant role in the management of advanced HNSCC, an understanding of their legacy is paramount. This historical review is not meant to exhaustively catalog every finding relating to HNSCC systemic therapy, but rather is meant to highlight important advances. Data Sources Case series and clinical trials available in the literature. Review Methods Historically significant series and trials evaluating HNSCC systemic therapy were evaluated. Results Standard regimens employed today are largely comprised of drugs discovered over 4 decades ago, although a number of recent phase III clinical trials have shown great promise, leading to the adoption of several new chemotherapeutic agents and treatment strategies. Conclusions These findings reinforce the importance of supporting further HNSCC drug discovery as modern treatment strategies using systemic therapy have resulted in measurable improvements in oncologic outcomes. Laryngoscope, 127:2565–2569, 2017 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text